Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

Phase

N/A

Condition

Adenocarcinoma

Non-small Cell Lung Cancer

Lung Cancer

Treatment

N/A

Clinical Study ID

NCT06441357

TDFS20240328

Ages > 18
All Genders

Study Summary

The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung adenocarcinomas, which could assist clinical decision making for surgery operation indication and strategy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

patients older than 18 years old with pulmonary nodules (diameter≤3 cm).
pathologically confirmed as lung adenocarcinoma.
without history of other malignancies.
accurate hematocrit within 1 week before contrast enhanced dual energy CTexamination.

Exclusion

Exclusion Criteria:

with a history of allergy to iodine contrast agents and other reasons who are unableto complete the examination.
without histopathology of invasion stage, such as AAH, AIS, MIA and IAC.
history of chemotherapy, radiotherapy, or other anti-tumor therapy before contrastenhanced dual energy CT.
poor image quality.
contrast enhanced dual energy CT scans ≥ 4 weeks before surgery.

Study Design

June 01, 2024

June 30, 2026

Study Description

Although progression of lung adenocarcinoma (LUAD) depends on driver mutations, it is also affected by tumor microenvironment (TME), including vessels, immune cells and extracellular matrix (ECM). As major constituent of TME, ECM mediates interactions between cancer cells and stromal cells, promotes angiogenesis, epithelial-mesenchymal transition, causes metastasis and resistance to immune therapy. Along with the progression of LUAD histologic stages, from atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS) to minimally invasive adenocarcinoma (MIA), and finally to invasive adenocarcinoma (IA), the composition of the ECM changes a lot, which has some characterizations same as interstitial pulmonary fibrosis. Hence, identifying the pathological ECM status may help differentiating the invasiveness of lung adenocarcinomas.

Based on the theory that in delay phase, the contrast medium is evenly distributed in the intravascular and extravascular-extracellular spaces and not entering the cell, extracellular volume (ECV) fraction is considered as a potential quantitative imaging parameter for ECM. It has been confirmed that ECV fraction is highly consistent with pathological fibrosis in cardiac and hepatic diseases. In other lesions with fibrosis such as pancreatic and thymic epithelial tumors, ECV fraction also has positive effects in malignancy prediction. It has been verified that ECV fraction is capable of differentiating lung cancer with benign lung lesions and classifying lung cancers into three subtypes. However, there has yet no study testified it as an invasion predictor.

The core purpose of this study is to investigate whether ECV fraction can distinguish precancerous lesions from early-stage lung adenocarcinomas and compare it with other confirmed radiological features in prediction performance, which is clinically meaningful regarding optimal treatment selection and avoidance of unnecessary surgical procedures.

Connect with a study center

Tangdu Hospital
Xi'an, Shaanxi 710038
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.